Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Investment Advisor, Morningside Ventures
Jason Dinges is currently an investment advisor at Morningside Technology Advisory LLC, which he joined in 2011. Dr. Dinges is also a director of several biopharmaceutical or biotechnology companies across a broad spectrum of therapeutic areas including: Kezar Life Sciences, Enyo Pharma, CellCentric, Pinteon Therapeutics, Cognito Therapeutics, Cancer Targeting Systems, Matatu, Bacainn Biotherapeutics, ClearB Therapeutics, and Alms Therapeutics. He has also facilitated multiple financings for private companies. From 2006 to 2011, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology, and Pharmaceutical practice group. Dr. Dinges received his Ph.D. in genetics from Iowa State University and a J.D., with highest distinction, from the University of Iowa College of Law.